3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase NA
1
Phase 2/3
1
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
5
Other hematologic neoplasm
4
CNS
3
Gynecologic
2
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Plasma cell
1
Myeloid
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Conditions
Head and Neck Neoplasms
32
Squamous Cell Carcinoma of Head and Neck
24
Nasopharyngeal Carcinoma
10
Mouth Neoplasms
10
Thyroid Neoplasms
9
Oropharyngeal Neoplasms
9
Laryngeal Neoplasms
8
Ovarian Neoplasms
5
Lung Neoplasms
5
Hypopharyngeal Neoplasms
5
Colorectal Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Melanoma
4
Carcinoma, Squamous Cell
4
Carcinoma
4
Thyroid Carcinoma, Anaplastic
3
Thyroid Cancer, Papillary
3
Recurrence
3
Neoplasms, Squamous Cell
3
Nasopharyngeal Neoplasms
3
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomatitis
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Parathyroid Neoplasms
2
Interventions
trametinib
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoproliferative Disorders
×
Head & Neck
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled